Owing to constant developments and challenges in the life sciences industry, stakeholders must continue to be adaptable, innovative, and competitive to thrive. Industry leaders must reconsider their strategic positions annually by understanding the main forces behind the transformation, including potential, challenges, and drivers.

• How are Contract Development and Manufacturing Organizations (CDMOs) augmenting their competencies in new modalities?
• In what ways do decentralized clinical trials (DCTs) enhance efficiency for cell and gene therapies (CGTs) and rare disorders?
• How is real-world insight (RWI) emerging as a strategic tool for reimagining commercial strategies?